{
  "schema_version": 1,
  "nct_id": "NCT06875193",
  "title": "DM Treatment to Evaluate the Efficacy and Safety of Dapagliflozin or Pioglitazone in Patients with Type 2 Diabetes",
  "status": "RECRUITING",
  "conditions": [
    "Type2diabetes"
  ],
  "source": {
    "name": "ClinicalTrials.gov",
    "nct_id": "NCT06875193",
    "url": "https://clinicaltrials.gov/study/NCT06875193",
    "retrieved": "2026-11-16",
    "modified": "Eligibility criteria structured and coded (SNOMED CT, LOINC, RxNorm) by ChartStays from the ClinicalTrials.gov text; the original text is kept unchanged in eligibility.criteria_text. Criteria curated by the project team, not reviewed by clinicians; pre-screening only.",
    "last_update_posted": "2025-03-17"
  },
  "eligibility": {
    "criteria_text": "Inclusion Criteria:\n\n* Patients with type 2 diabetes who are 19 years of age or older at the date of written consent\n* Subjects who Receiving a stable dose of metformin and a DPP-4 inhibitor for at least the last 8 weeks at the time of screening\n* HbA1c ≤ 7.0% ≤ HbA1c \\< 10% at time of screening\n* BMI ≤ 18.5 kg/m2 ≤ 40 kg/m2 at time of screening\n* Subjects fully explained and understood the purpose and methods of this study and voluntarily gave written informed consent\n\nExclusion Criteria:\n\n* Patients with type 1 diabetes\n* Have a BMI \\> 40 kg/m2\n* Subjects who have moderate (Stage 3b) or severe kidney disease or an estimated glomerular filtration rate (eGFR, using the CKD-EPI formula) \\< 45 mL/min/1.73 m2\n* Patients with end stage renal disease or patients on dialysis\n* Patients with uncontrolled heart failure (NYHA class III - IV)\n* Patients with history of uncontrolled arrhythmia, myocardial infarction, unstable angina, coronary artery bypass graft surgery, cerebrovascular disease within 24 weeks prior to the screening visit\n* Patients with acute or chronic metabolic acidosis, including lactic acidosis, diabetic ketoacidosis (DKA) with or without coma, and patients with a history of ketoacidosis\n* Patients with diabetic coma or precoma\n* Patients with a history of severe hypoglycemia while taking metformin and DPP-4 inhibitors.\n* Patients with hematuria\n* Patients who receiving treatment for thyroid dysfunction at the time of screening\n* Malnourished, starving, or debilitated subjects\n* Patients with pituitary insufficiency or adrenal insufficiency\n* Patients with clinically significant hepatic disease with AST or ALT greater than 3 times the upper limit of normal\n* Patients with severe infectious diseases, perioperative, or clinically significant trauma\n* Have a history of substance abuse\n* Patients receiving insulin or sulfonylurea, thiazolidinedione, SGLT2 inhibitor, GLP-1 receptor agonist within 8 weeks prior to the screening visit\n* Patients who have received more than 2 consecutive weeks of corticosteroids within 8 weeks at the time of screening or who require treatment requiring repeated use of corticosteroids\n* Patients with a history of malignancy within the last 5 years\n* Participation in any other clinical trial within 12 weeks of screening in which an investigational drug or investigational medical device was administered or applied\n* Pregnant and breastfeeding women\n* Hypersensitivity to any of the drugs and components, including metformin, DPP-4 inhibitors, dapagliflozin, TZDs, sulfonylurea class of drugs, or any of the ingredients\n* Patients with genetic problems such as galactose intolerance, Lapp lactose deficiency, or glucose-galactose mal-absorption.\n* Any other person deemed by the investigator to be unsuitable for participation in the study",
    "sex": "ALL",
    "minimum_age": "19 Years",
    "maximum_age": null,
    "healthy_volunteers": false
  },
  "structured": [
    {
      "id": "inc-0a",
      "type": "inclusion",
      "kind": "age",
      "label": "Age 19 years or older",
      "source_text": "ClinicalTrials.gov age limits: 19 Years minimum, none maximum",
      "min": 19,
      "max": null,
      "unit": "years"
    },
    {
      "kind": "condition",
      "label": "Type 2 diabetes",
      "primary": true,
      "codes": {
        "snomed": [
          "44054006"
        ]
      },
      "id": "inc-1",
      "type": "inclusion",
      "source_text": "Patients with type 2 diabetes who are 19 years of age or older at the date of written consent"
    },
    {
      "kind": "medication",
      "label": "Taking metformin",
      "rxnorm": [
        "860975"
      ],
      "note": "Only the metformin product found in the Synthea sample (RxNorm 860975, metformin ER 500 mg, the only metformin code in the sample) is recognised; other metformin products rely on the free text; the DPP-4 inhibitor and dose stability are not checked.",
      "id": "inc-2a",
      "type": "inclusion",
      "source_text": "Subjects who Receiving a stable dose of metformin and a DPP-4 inhibitor for at least the last 8 weeks at the time of screening"
    },
    {
      "kind": "lab",
      "label": "HbA1c 7.0% or higher",
      "loinc": "4548-4",
      "op": "gte",
      "value": 7,
      "unit": "%",
      "note": "Interpreted from garbled source text (\"HbA1c ≤ 7.0% ≤ HbA1c < 10%\") as 7.0% to below 10%.",
      "id": "inc-3a",
      "type": "inclusion",
      "source_text": "HbA1c ≤ 7.0% ≤ HbA1c < 10% at time of screening"
    },
    {
      "kind": "lab",
      "label": "HbA1c below 10%",
      "loinc": "4548-4",
      "op": "lt",
      "value": 10,
      "unit": "%",
      "id": "inc-3b",
      "type": "inclusion",
      "source_text": "HbA1c ≤ 7.0% ≤ HbA1c < 10% at time of screening"
    },
    {
      "kind": "lab",
      "label": "BMI 18.5 to 40 kg/m2",
      "loinc": "39156-5",
      "op": "between",
      "value": [
        18.5,
        40
      ],
      "unit": "kg/m2",
      "note": "Interpreted from garbled source text (\"BMI ≤ 18.5 kg/m2 ≤ 40 kg/m2\") as 18.5 to 40 kg/m2.",
      "id": "inc-4a",
      "type": "inclusion",
      "source_text": "BMI ≤ 18.5 kg/m2 ≤ 40 kg/m2 at time of screening"
    },
    {
      "kind": "lab",
      "label": "BMI above 40 kg/m2",
      "loinc": "39156-5",
      "op": "gt",
      "value": 40,
      "unit": "kg/m2",
      "id": "exc-2",
      "type": "exclusion",
      "source_text": "Have a BMI > 40 kg/m2"
    },
    {
      "kind": "lab",
      "label": "eGFR below 45 mL/min/1.73m2",
      "loinc": "33914-3",
      "op": "lt",
      "value": 45,
      "unit": "mL/min/{1.73_m2}",
      "note": "The study uses CKD-EPI; Synthea records eGFR by the MDRD formula (LOINC 33914-3).",
      "id": "exc-3a",
      "type": "exclusion",
      "source_text": "Subjects who have moderate (Stage 3b) or severe kidney disease or an estimated glomerular filtration rate (eGFR, using the CKD-EPI formula) < 45 mL/min/1.73 m2"
    },
    {
      "kind": "medication",
      "label": "Receiving insulin",
      "rxnorm": [
        "106892"
      ],
      "note": "Only the insulin product found in the Synthea sample (RxNorm 106892) is recognised; other drug classes rely on the free text.",
      "id": "exc-17a",
      "type": "exclusion",
      "source_text": "Patients receiving insulin or sulfonylurea, thiazolidinedione, SGLT2 inhibitor, GLP-1 receptor agonist within 8 weeks prior to the screening visit"
    }
  ],
  "free_text": [
    {
      "id": "inc-2",
      "type": "inclusion",
      "text": "Subjects who Receiving a stable dose of metformin and a DPP-4 inhibitor for at least the last 8 weeks at the time of screening"
    },
    {
      "id": "inc-3",
      "type": "inclusion",
      "text": "HbA1c ≤ 7.0% ≤ HbA1c < 10% at time of screening"
    },
    {
      "id": "inc-4",
      "type": "inclusion",
      "text": "BMI ≤ 18.5 kg/m2 ≤ 40 kg/m2 at time of screening"
    },
    {
      "id": "inc-5",
      "type": "inclusion",
      "text": "Subjects fully explained and understood the purpose and methods of this study and voluntarily gave written informed consent"
    },
    {
      "id": "exc-1",
      "type": "exclusion",
      "text": "Patients with type 1 diabetes"
    },
    {
      "id": "exc-3",
      "type": "exclusion",
      "text": "Subjects who have moderate (Stage 3b) or severe kidney disease or an estimated glomerular filtration rate (eGFR, using the CKD-EPI formula) < 45 mL/min/1.73 m2"
    },
    {
      "id": "exc-4",
      "type": "exclusion",
      "text": "Patients with end stage renal disease or patients on dialysis"
    },
    {
      "id": "exc-5",
      "type": "exclusion",
      "text": "Patients with uncontrolled heart failure (NYHA class III - IV)"
    },
    {
      "id": "exc-6",
      "type": "exclusion",
      "text": "Patients with history of uncontrolled arrhythmia, myocardial infarction, unstable angina, coronary artery bypass graft surgery, cerebrovascular disease within 24 weeks prior to the screening visit"
    },
    {
      "id": "exc-7",
      "type": "exclusion",
      "text": "Patients with acute or chronic metabolic acidosis, including lactic acidosis, diabetic ketoacidosis (DKA) with or without coma, and patients with a history of ketoacidosis"
    },
    {
      "id": "exc-8",
      "type": "exclusion",
      "text": "Patients with diabetic coma or precoma"
    },
    {
      "id": "exc-9",
      "type": "exclusion",
      "text": "Patients with a history of severe hypoglycemia while taking metformin and DPP-4 inhibitors."
    },
    {
      "id": "exc-10",
      "type": "exclusion",
      "text": "Patients with hematuria"
    },
    {
      "id": "exc-11",
      "type": "exclusion",
      "text": "Patients who receiving treatment for thyroid dysfunction at the time of screening"
    },
    {
      "id": "exc-12",
      "type": "exclusion",
      "text": "Malnourished, starving, or debilitated subjects"
    },
    {
      "id": "exc-13",
      "type": "exclusion",
      "text": "Patients with pituitary insufficiency or adrenal insufficiency"
    },
    {
      "id": "exc-14",
      "type": "exclusion",
      "text": "Patients with clinically significant hepatic disease with AST or ALT greater than 3 times the upper limit of normal"
    },
    {
      "id": "exc-15",
      "type": "exclusion",
      "text": "Patients with severe infectious diseases, perioperative, or clinically significant trauma"
    },
    {
      "id": "exc-16",
      "type": "exclusion",
      "text": "Have a history of substance abuse"
    },
    {
      "id": "exc-17",
      "type": "exclusion",
      "text": "Patients receiving insulin or sulfonylurea, thiazolidinedione, SGLT2 inhibitor, GLP-1 receptor agonist within 8 weeks prior to the screening visit"
    },
    {
      "id": "exc-18",
      "type": "exclusion",
      "text": "Patients who have received more than 2 consecutive weeks of corticosteroids within 8 weeks at the time of screening or who require treatment requiring repeated use of corticosteroids"
    },
    {
      "id": "exc-19",
      "type": "exclusion",
      "text": "Patients with a history of malignancy within the last 5 years"
    },
    {
      "id": "exc-20",
      "type": "exclusion",
      "text": "Participation in any other clinical trial within 12 weeks of screening in which an investigational drug or investigational medical device was administered or applied"
    },
    {
      "id": "exc-21",
      "type": "exclusion",
      "text": "Pregnant and breastfeeding women"
    },
    {
      "id": "exc-22",
      "type": "exclusion",
      "text": "Hypersensitivity to any of the drugs and components, including metformin, DPP-4 inhibitors, dapagliflozin, TZDs, sulfonylurea class of drugs, or any of the ingredients"
    },
    {
      "id": "exc-23",
      "type": "exclusion",
      "text": "Patients with genetic problems such as galactose intolerance, Lapp lactose deficiency, or glucose-galactose mal-absorption."
    },
    {
      "id": "exc-24",
      "type": "exclusion",
      "text": "Any other person deemed by the investigator to be unsuitable for participation in the study"
    }
  ],
  "requested_fields_for_inquiry": [
    "age",
    "conditions",
    "medications",
    "labs:4548-4",
    "labs:39156-5",
    "labs:33914-3"
  ],
  "curation": {
    "method": "manual"
  }
}
